 | • レポートコード：MRC2103G043 • 出版社/出版日：Transparency Market Research / 2020年10月30日 • レポート形態：英文、PDF、124ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Site Licence | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Enterprisewide Licence | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、世界のがん診断市場を広く調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、方法別（生検、内視鏡検査、画像、腫瘍バイオマーカーテスト）分析、用途別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の構成でまとめております。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・キーインサイト ・がん診断の世界市場規模：方法別（生検、内視鏡検査、画像、腫瘍バイオマーカーテスト） ・がん診断の世界市場規模：用途別 ・がん診断の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Global Cancer Diagnostics Market – Scope of Report
TMR’s report on the global cancer diagnostics market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global cancer diagnostics market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global cancer diagnostics market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global cancer diagnostics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global cancer diagnostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global cancer diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global cancer diagnostics market.
The report delves into the competitive landscape of the global cancer diagnostics market. Key players operating in the global cancer diagnostics market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global cancer diagnostics market that have been profiled in this report.
Key Questions Answered in Global Cancer Diagnostics Market Report
What is the scope of growth of product companies in the global cancer diagnostics market?
What will be the Y-o-Y growth of the global cancer diagnostics market between 2019 and 2027?
What is the influence of changing trends in technologies on the global cancer diagnostics market?
Will North America continue to be the most profitable market for cancer diagnostics providers?
Which factors are anticipated to hamper the growth of the global cancer diagnostics market during the forecast period?
Which are the leading companies in the global cancer diagnostics market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global cancer diagnostics market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global cancer diagnostics market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the cancer diagnostics market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the cancer diagnostics market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global cancer diagnostics market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global cancer diagnostics market more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objective
1.4. Research Highlight
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Development
4.2. Overview
4.3. Market Dynamic
4.3.1. Driver
4.3.2. Restraint
4.3.3. Opportunitie
4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Regulatory Scenario and Reimbursement
5.2. Cancer Epidemiology
5.3. List of active market participants (suppliers/distributors/manufacturers/vendors)
6. Global Cancer Diagnostics Market Analysis and Forecast, by Method
6.1. Introduction & Definition
6.1.1. Key Findings / Development
6.2. Global Cancer Diagnostics Market Value Forecast, by Method, 2017–2027
6.2.1. Biopsy
6.2.1.1. Bone Marrow Biopsy
6.2.1.2. Needle Biopsy
6.2.1.3. Endoscopic Biopsy
6.2.2. Endoscopy
6.2.2.1. Bronchoscopy
6.2.2.2. Colonoscopy
6.2.2.3. Sigmoidoscopy
6.2.2.4. Colposcopy
6.2.2.5. Other
6.2.3. Imaging
6.2.3.1. MRI Scan
6.2.3.2. PET Scan
6.2.3.3. CT Scan
6.2.3.4. Mammography
6.2.3.5. Ultrasound
6.2.4. Tumor Biomarker Test
6.2.4.1. PSA Test
6.2.4.2. CTC Test
6.2.4.3. AFP Test
6.2.4.4. CA 19-9
6.2.4.5. CA 125
6.2.4.6. EGFR
6.2.4.7. HER2
6.2.4.8. CEA
6.2.4.9. BRCA
6.2.4.10. KRA
6.2.4.11. ALK
6.3. Global Cancer Diagnostics Market Attractiveness, by Method
7. Global Cancer Diagnostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.1.1. Key Findings / Development
7.2. Global Cancer Diagnostics Market Value Forecast, by Application, 2017–2027
7.2.1. Blood Cancer
7.2.2. Breast Cancer
7.2.3. Colorectal Cancer
7.2.4. Kidney Cancer
7.2.5. Liver Cancer
7.2.6. Lung Cancer
7.2.7. Ovarian Cancer
7.2.8. Pancreatic Cancer
7.2.9. Prostate Cancer
7.3. Global Cancer Diagnostics Market Attractiveness, by Application
8. Global Cancer Diagnostics Market Analysis and Forecast, by Region
8.1. Key Finding
8.2. Global Cancer Diagnostics Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. North America Cancer Diagnostics Market Attractiveness, by Region
9. North America Cancer Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Finding
9.2. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
9.2.1. Biopsy
9.2.1.1. Bone Marrow Biopsy
9.2.1.2. Needle Biopsy
9.2.1.3. Endoscopic Biopsy
9.2.2. Endoscopy
9.2.2.1. Bronchoscopy
9.2.2.2. Colonoscopy
9.2.2.3. Sigmoidoscopy
9.2.2.4. Colposcopy
9.2.2.5. Other
9.2.3. Imaging
9.2.3.1. MRI Scan
9.2.3.2. PET Scan
9.2.3.3. CT Scan
9.2.3.4. Mammography
9.2.3.5. Ultrasound
9.2.4. Tumor Biomarker Test
9.2.4.1. PSA Test
9.2.4.2. CTC Test
9.2.4.3. AFP Test
9.2.4.4. CA 19-9
9.2.4.5. CA 125
9.2.4.6. EGFR
9.2.4.7. HER2
9.2.4.8. CEA
9.2.4.9. BRCA
9.2.4.10. KRA
9.2.4.11. ALK
9.3. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
9.3.1. Blood Cancer
9.3.2. Breast Cancer
9.3.3. Colorectal Cancer
9.3.4. Kidney Cancer
9.3.5. Liver Cancer
9.3.6. Lung Cancer
9.3.7. Ovarian Cancer
9.3.8. Pancreatic Cancer
9.3.9. Prostate Cancer
9.4. North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Cancer Diagnostics Market Attractiveness Analysi
9.5.1. By Method
9.5.2. By Application
9.5.3. By Country
10. Europe Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Finding
10.2. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
10.2.1. Biopsy
10.2.1.1. Bone Marrow Biopsy
10.2.1.2. Needle Biopsy
10.2.1.3. Endoscopic Biopsy
10.2.2. Endoscopy
10.2.2.1. Bronchoscopy
10.2.2.2. Colonoscopy
10.2.2.3. Sigmoidoscopy
10.2.2.4. Colposcopy
10.2.2.5. Other
10.2.3. Imaging
10.2.3.1. MRI Scan
10.2.3.2. PET Scan
10.2.3.3. CT Scan
10.2.3.4. Mammography
10.2.3.5. Ultrasound
10.2.4. Tumor Biomarker Test
10.2.4.1. PSA Test
10.2.4.2. CTC Test
10.2.4.3. AFP Test
10.2.4.4. CA 19-9
10.2.4.5. CA 125
10.2.4.6. EGFR
10.2.4.7. HER2
10.2.4.8. CEA
10.2.4.9. BRCA
10.2.4.10. KRA
10.2.4.11. ALK
10.3. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
10.3.1. Blood Cancer
10.3.2. Breast Cancer
10.3.3. Colorectal Cancer
10.3.4. Kidney Cancer
10.3.5. Liver Cancer
10.3.6. Lung Cancer
10.3.7. Ovarian Cancer
10.3.8. Pancreatic Cancer
10.3.9. Prostate Cancer
10.4. Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Europe Cancer Diagnostics Market Attractiveness Analysi
10.5.1. By Method
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Finding
11.2. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
11.2.1. Biopsy
11.2.1.1. Bone Marrow Biopsy
11.2.1.2. Needle Biopsy
11.2.1.3. Endoscopic Biopsy
11.2.2. Endoscopy
11.2.2.1. Bronchoscopy
11.2.2.2. Colonoscopy
11.2.2.3. Sigmoidoscopy
11.2.2.4. Colposcopy
11.2.2.5. Other
11.2.3. Imaging
11.2.3.1. MRI Scan
11.2.3.2. PET Scan
11.2.3.3. CT Scan
11.2.3.4. Mammography
11.2.3.5. Ultrasound
11.2.4. Tumor Biomarker Test
11.2.4.1. PSA Test
11.2.4.2. CTC Test
11.2.4.3. AFP Test
11.2.4.4. CA 19-9
11.2.4.5. CA 125
11.2.4.6. EGFR
11.2.4.7. HER2
11.2.4.8. CEA
11.2.4.9. BRCA
11.2.4.10. KRA
11.2.4.11. ALK
11.3. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
11.3.1. Blood Cancer
11.3.2. Breast Cancer
11.3.3. Colorectal Cancer
11.3.4. Kidney Cancer
11.3.5. Liver Cancer
11.3.6. Lung Cancer
11.3.7. Ovarian Cancer
11.3.8. Pancreatic Cancer
11.3.9. Prostate Cancer
11.4. Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Cancer Diagnostics Market Attractiveness Analysi
11.5.1. By Method
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Finding
12.2. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
12.2.1. Biopsy
12.2.1.1. Bone Marrow Biopsy
12.2.1.2. Needle Biopsy
12.2.1.3. Endoscopic Biopsy
12.2.2. Endoscopy
12.2.2.1. Bronchoscopy
12.2.2.2. Colonoscopy
12.2.2.3. Sigmoidoscopy
12.2.2.4. Colposcopy
12.2.2.5. Other
12.2.3. Imaging
12.2.3.1. MRI Scan
12.2.3.2. PET Scan
12.2.3.3. CT Scan
12.2.3.4. Mammography
12.2.3.5. Ultrasound
12.2.4. Tumor Biomarker Test
12.2.4.1. PSA Test
12.2.4.2. CTC Test
12.2.4.3. AFP Test
12.2.4.4. CA 19-9
12.2.4.5. CA 125
12.2.4.6. EGFR
12.2.4.7. HER2
12.2.4.8. CEA
12.2.4.9. BRCA
12.2.4.10. KRA
12.2.4.11. ALK
12.3. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
12.3.1. Blood Cancer
12.3.2. Breast Cancer
12.3.3. Colorectal Cancer
12.3.4. Kidney Cancer
12.3.5. Liver Cancer
12.3.6. Lung Cancer
12.3.7. Ovarian Cancer
12.3.8. Pancreatic Cancer
12.3.9. Prostate Cancer
12.4. Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America Latin America
12.5. Latin America Cancer Diagnostics Market Attractiveness Analysi
12.5.1. By Method
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Finding
13.2. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Method, 2017–2027
13.2.1. Biopsy
13.2.1.1. Bone Marrow Biopsy
13.2.1.2. Needle Biopsy
13.2.1.3. Endoscopic Biopsy
13.2.2. Endoscopy
13.2.2.1. Bronchoscopy
13.2.2.2. Colonoscopy
13.2.2.3. Sigmoidoscopy
13.2.2.4. Colposcopy
13.2.2.5. Other
13.2.3. Imaging
13.2.3.1. MRI Scan
13.2.3.2. PET Scan
13.2.3.3. CT Scan
13.2.3.4. Mammography
13.2.3.5. Ultrasound
13.2.4. Tumor Biomarker Test
13.2.4.1. PSA Test
13.2.4.2. CTC Test
13.2.4.3. AFP Test
13.2.4.4. CA 19-9
13.2.4.5. CA 125
13.2.4.6. EGFR
13.2.4.7. HER2
13.2.4.8. CEA
13.2.4.9. BRCA
13.2.4.10. KRA
13.2.4.11. ALK
13.3. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017–2027
13.3.1. Blood Cancer
13.3.2. Breast Cancer
13.3.3. Colorectal Cancer
13.3.4. Kidney Cancer
13.3.5. Liver Cancer
13.3.6. Lung Cancer
13.3.7. Ovarian Cancer
13.3.8. Pancreatic Cancer
13.3.9. Prostate Cancer
13.4. Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countrie
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Cancer Diagnostics Market Attractiveness Analysi
13.5.1. By Method
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (by Tier and Size of companies)
14.2. Market Share / Position Analysis, by Company, 2018
14.3. Competitive Business Strategie
14.4. Company Profile
14.4.1. Abbott
14.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.1.2. Growth Strategie
14.4.1.3. SWOT Analysi
14.4.2. Ambry Genetics
14.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.2.2. Growth Strategie
14.4.2.3. SWOT Analysi
14.4.3. AstraZeneca plc
14.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.3.2. Growth Strategie
14.4.3.3. SWOT Analysi
14.4.4. bioMeriux SA
14.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.4.2. Growth Strategie
14.4.4.3. SWOT Analysi
14.4.5. Eli Lilly and Company
14.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.5.2. Growth Strategie
14.4.5.3. SWOT Analysi
14.4.6. Genoptix, Inc
14.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.6.2. Growth Strategie
14.4.6.3. SWOT Analysi
14.4.7. GlaxoSmithKline plc
14.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.7.2. Growth Strategie
14.4.7.3. SWOT Analysi
14.4.8. F. Hoffmann-La Roche Ltd
14.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.8.2. Growth Strategie
14.4.8.3. SWOT Analysi
14.4.9. Pfizer, Inc
14.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.4.9.2. Growth Strategie
14.4.9.3. SWOT Analysis
Table 1List of Abbreviation
Table 2Market Snapshot: Global Cancer Diagnostics Market
Table 3List of Cancer Risk Factors
Table 4Estimated Incidence, 1 year, 2 years and 5 years survival
Table 5Breast Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
Table 6Lung Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
Table 7Colorectal Cancer Companion Diagnostics (CDx), Manufacturers and Target Drugs
Table 8Summary of Type of Diagnostics Test in the U.S.
Table 9Event Impact Analysis: Global Cancer Diagnostics Market, 2017-2027
Table 10Global Cancer Diagnostics Market Revenue, by Method, 2017-2027 (USD) Million
Table 11Global Cancer Diagnostics Market Revenue, by Application, 2017-2027 (USD) Million
Table 12Global Cancer Diagnostics Market Revenue, by Geography, 2017-2027 (USD) Million